Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch
Source: SeekingAlpha
2026-05-14 11:10:07 ET
More on Aquestive Therapeutics
- Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
- Aquestive Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
- Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation
- Aquestive Therapeutics GAAP EPS of -$0.07 beats by $0.07, revenue of $14.4M beats by $3.5M
- Aquestive Therapeutics Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch
Aquestive Therapeutics Inc.
NASDAQ: AQST
AQST Trading
11.74% G/L:
$4.665 Last:
3,452,074 Volume:
$4.75 Open:
AQST Latest News
May 13, 2026 04:01:00 pm
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026 09:31:25 am
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
AQST Stock Data
$477,556,785
111,815,853
0.67%
63
N/A
Pharmaceuticals
Healthcare
US
Warren
